Advocacy intelligence hub — real-time data for patient organizations
VIGADRONE: New indication approved
VIGABATRIN: New indication approved
VIGABATRIN: New indication approved
VIGABATRIN: New indication approved
VIGABATRIN: New indication approved
VIGABATRIN: New indication approved
VIGABATRIN: New indication approved
VIGABATRIN: New indication approved
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Patient Assistance Programs1
Cimetidine
Chartwell RX, LLC
Cimetidine
(CIMETIDINE)Orphan drugstandardChartwell RX, LLC
Histamine-2 Receptor Antagonist [EPC]
Everolimus
(EVEROLIMUS)Orphan drugstandardBreckenridge Pharmaceutical, Inc.
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pat...
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
FDA Approves VIGABATRIN
VIGABATRIN (VIGABATRIN) received FDA approval.
James C Yao
SWOG Cancer Research Network
Gabriele Capurso, PhD
IRCCS Ospedale San Raffaele
Daniel M Halperin, MD, MD
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Wu-Chou Su
National Cheng Kung University Hospital,Taiwan
Dan P Zandberg, MD
UPMC Hillman Cancer Center
📍 BALTIMORE, MD
Dan Zandberg, MD, MD
UPMC Hillman Cancer Center
📍 BALTIMORE, MD